NasdaqGM:RYTMBiotechs
Is RBC’s TRANSCEND-Driven Coverage and FDA Delay Altering The Investment Case For Rhythm (RYTM)?
In recent days, Rhythm Pharmaceuticals drew attention as RBC Capital Markets initiated coverage following the positive Phase 3 TRANSCEND results for setmelanotide in hypothalamic obesity and the prior FDA decision to extend review of its supplemental New Drug Application to March 20, 2026.
At the same time, insider selling by the CFO and a full year of insider share disposals, alongside renewed institutional and analyst interest, has sharpened focus on how regulatory progress and ownership...